Showing 261-270 of 739 results for "".
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- Study Seeks to Harness the Power of Probiotics to Treat Eczemahttps://practicaldermatology.com/news/study-seeks-to-harness-the-power-of-probiotics-to-treat-eczema/2457778/A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics. However,
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- FDA Grants Extended Clearance of the Describe Patch for Tattoo Removalhttps://practicaldermatology.com/news/fda-grants-extended-clearance-of-the-describe-patch-for-tattoo-removal/2457960/Merz North America’s DESCRIBE® PFD Patch is now cleared by the Food and Drug Administration (FDA) for all commonly used lasers for tattoo removal. The new FDA clearance also extends the shelf life of the Patch from two years
- Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infectionshttps://practicaldermatology.com/news/paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met-fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections/2458118/Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Nutrition for Healing Introduces MEND Cosmetic to Support Improved Healing & Recovery From Cosmetic Surgeryhttps://practicaldermatology.com/news/nutrition-for-healing-introduces-mend-cosmetic-to-support-improved-healing-recovery-from-cosmetic-surgery/2458201/Nutrition For Healing LLC launched its new MEND Cosmetic, which is now available through cosmetic surgeons worldwide. The all natural formula, a blend of clinically researched, proven ingredients designed specifically to support healing from cosmetic surgery,
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://practicaldermatology.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2458219/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi